These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29351984)

  • 1. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.
    Leung N; Thomé SD; Dispenzieri A
    Haematologica; 2018 Mar; 103(3):e135-e137. PubMed ID: 29351984
    [No Abstract]   [Full Text] [Related]  

  • 2. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
    Ghilardi G; Stussi G; Mazzucchelli L; Röcken C; Rossi D; Gerber B
    Amyloid; 2019 Sep; 26(3):173-174. PubMed ID: 31232114
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.
    Gran C; Borg Bruchfeld J; Ellin F; Nahi H
    Acta Haematol; 2020; 143(5):500-503. PubMed ID: 31896106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
    Premkumar V; Comenzo R; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):686-688. PubMed ID: 31399374
    [No Abstract]   [Full Text] [Related]  

  • 5. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
    Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
    Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax for the treatment of translocation (11;14) AL amyloidosis.
    Sidiqi MH; Al Saleh AS; Leung N; Jevremovic D; Aljama MA; Gonsalves WI; Buadi FK; Kourelis TV; Warsame R; Muchtar E; Hobbs MA; Lacy MQ; Dingli D; Go RS; Hayman SR; Rajkumar SV; Dispenzieri A; Gertz MA; Kumar SK; Fonseca R; Kapoor P
    Blood Cancer J; 2020 May; 10(5):55. PubMed ID: 32393733
    [No Abstract]   [Full Text] [Related]  

  • 8. Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?
    Yip PL; Lau JSM; Lam CP
    Int J Hematol; 2020 Aug; 112(2):234-237. PubMed ID: 32207051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
    Wong KY; Chim CS
    J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
    Jelinek T; Popkova T; Duras J; Mihalyova J; Kascak M; Benkova K; Plonkova H; Cerna L; Koristek Z; Simicek M; Hajek R
    Hematol Oncol; 2020 Aug; 38(3):412-414. PubMed ID: 32323881
    [No Abstract]   [Full Text] [Related]  

  • 11. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
    Boccon-Gibod C; Talbot A; Le Bras F; Frenzel L; Royer B; Harel S; Lombion N; Belhadj K; Cuccuini W; Arnulf B
    Br J Haematol; 2020 May; 189(3):e73-e76. PubMed ID: 32012229
    [No Abstract]   [Full Text] [Related]  

  • 12. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
    Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
    Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
    Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
    J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary plasma cell leukaemia treated with single agent venetoclax.
    Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
    Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
    Zanwar S; Gertz MA; Muchtar E; Buadi FK; Kourelis T; Gonsalves W; Go RS; Hayman S; Kapoor P; Binder M; Cook J; Dingli D; Leung N; Lin Y; Warsame R; Fonder A; Hobbs M; Hwa YL; Kyle RA; Rajkumar SV; Kumar S; Dispenzieri A
    Leukemia; 2024 Jun; 38(6):1423-1426. PubMed ID: 38594348
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.
    Dima D; Hughes M; Orland M; Ullah F; Goel U; Anwer F; Raza S; Mazzoni S; Bhutani D; Williams L; Lentzsch S; Samaras C; Valent J; Chakraborty R; Khouri J
    Amyloid; 2024 Sep; 31(3):195-201. PubMed ID: 38956891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.
    Freise KJ; Jones AK; Verdugo ME; Menon RM; Maciag PC; Salem AH
    Clin Pharmacol Ther; 2017 Dec; 102(6):970-976. PubMed ID: 28419431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
    Zhang Y; Duncanson L; Brayer J; Reu F; Hansen D; Alsina M; Nishihori T; Ochoa-Bayona J; Liu H; Shain K; Thompson Z; Baz R; Blue B
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e770-e776. PubMed ID: 35504808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
    Avigan ZM; Joshua Richter Md
    Oncology (Williston Park); 2024 Jun; 38(6):239-241. PubMed ID: 38899981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.